Medicine and Dentistry
Ovarian Cancer
100%
Malignant Neoplasm
36%
PARP Inhibitor
32%
Overall Survival
30%
Neoplasm
27%
Gemcitabine
26%
Krukenberg Tumor
25%
Oncology
24%
Cancer
23%
Diseases
23%
BRCA1
22%
Homologous Recombination
19%
Progression Free Survival
19%
Clinical Trial
19%
Veliparib
16%
Niraparib
15%
Gynecological Oncology
14%
Phase II Trials
14%
Xenograft
13%
Biological Marker
12%
Adverse Event
12%
Paclitaxel
12%
Arm
12%
Monotherapy
12%
BRCA2
11%
Platinum-Resistant Ovarian Cancer
11%
Berzosertib
11%
Cancer Model
10%
Cancer Cell
9%
Cancer Treatment
9%
Triple Negative Breast Cancer
9%
Recurrent Ovarian Cancer
9%
Estrogen Receptor
9%
Letrozole
9%
Cediranib
9%
Olaparib
9%
Bevacizumab
9%
Placebo
9%
Pembrolizumab
9%
Uterine Cancer
9%
Clear Cell Carcinoma
9%
Fallopian Tube
8%
Immune Checkpoint Inhibitor
8%
Topotecan
8%
Cancer Therapy
8%
Neuropathy
7%
Fallopian Tube Cancer
7%
Primary Peritoneal Cancer
7%
Metastatic Carcinoma
7%
Carboplatin
6%
Keyphrases
Ovarian Cancer
58%
Phase II Trial
38%
PARP Inhibitor (PARPi)
33%
Gemcitabine
26%
Tumor
25%
Overall Survival
24%
NRG Oncology
23%
Advanced Ovarian Cancer
20%
Chemotherapy
19%
Bevacizumab
18%
Randomized Phase II Trial
18%
Phase II Study
17%
Veliparib
17%
Platinum Resistance
16%
Homologous Recombination Deficiency
15%
Niraparib
15%
Ovarian Cancer Patients
15%
Epithelial Ovarian Cancer
14%
High-grade Serous Ovarian Cancer (HGSOC)
14%
Progression-free Survival
14%
Gynecologic Oncology Group
14%
Group Studies
14%
Olaparib
14%
Breast Cancer Susceptibility Gene 1 (BRCA1)
12%
Primary Peritoneal Cancer
12%
Platinum-resistant Ovarian Cancer
12%
Malignancy
12%
Adverse Events
12%
Berzosertib
11%
Paclitaxel
11%
Ovarian Cancer Cells
11%
ATR Inhibitor
10%
BRCA1, BRCA2
10%
Objective Response Rate
10%
Insulin-like
10%
Growth Factors
9%
Patient-derived Xenograft
9%
Monotherapy
9%
A1 Receptor
9%
Tanespimycin
9%
Letrozole
9%
Oncologic Emergency
9%
Recurrent Ovarian Cancer
9%
Cediranib
9%
Akt Activation
9%
Clear Cell Carcinoma of the Ovary
9%
Estrogen Receptor-positive
9%
Pembrolizumab
9%
Platinum-refractory
9%
Randomized Placebo-controlled Trial
9%